Novo Nordisk A/S (NVO)
| Market Cap | 227.63B |
| Revenue (ttm) | 49.58B |
| Net Income (ttm) | 16.30B |
| Shares Out | 4.44B |
| EPS (ttm) | 3.67 |
| PE Ratio | 13.97 |
| Forward PE | 14.65 |
| Dividend | $1.23 (2.40%) |
| Ex-Dividend Date | Aug 18, 2025 |
| Volume | 11,883,980 |
| Open | 51.52 |
| Previous Close | 51.47 |
| Day's Range | 51.07 - 51.67 |
| 52-Week Range | 43.08 - 93.80 |
| Beta | 0.35 |
| Analysts | Buy |
| Price Target | 54.25 (+5.92%) |
| Earnings Date | Feb 4, 2026 |
About NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for NVO stock is "Buy." The 12-month stock price target is $54.25, which is an increase of 5.92% from the latest price.
News
Novo Nordisk's 'long game' on weight loss drugs sparks hope in science, but the Street is impatient
Novo Nordisk has had a difficult year as investors questioned the company's ability to translate its strides in pioneering GLP-1 drugs to financial gains. Scientists, however, say that Novo's medicine...
Novo cuts Wegovy prices in some Chinese provinces, local media reports
Danish drugmaker Novo Nordisk has nearly halved prices of its obesity drug Wegovy in some Chinese provinces, local media Yicai reported on Monday.
Novo Nordisk: Oral Weight-Loss To The Rescue
Novo Nordisk secured FDA approval for the first oral GLP-1 weight-loss drug, Wegovy, positioning it as a sector game changer. NVO's oral Wegovy pill demonstrated superior weight-loss efficacy versus E...
Potentially 12%-15% Consistent Income: Monthly Options Series (January 2026)
Selling options can generate 12-15% annual income but requires discipline, risk management, and due diligence. We explain why selling cash-covered puts and covered calls is a relatively safe choice fo...
Oral Wegovy Approval Is The Critical 2026 Lifeline Novo Nordisk Needs
Novo Nordisk A/S secured FDA approval for oral Wegovy, marking a pivotal expansion in the obesity treatment market. Oral GLP-1 therapies promise greater accessibility and a potentially larger addressa...
Novo Nordisk: The Real Comeback Starts Now With The Wegovy Pill
Novo Nordisk has finally received FDA approval for the Wegovy pill, aiming to regain ground in the obesity drugs market against Eli Lilly. NVO trades close to a 10-year low forward EBITDA multiple of ...
NVO Weight-Loss Pill Approved
2026 could see an explosion in weight loss drug use in the U.S. after the FDA approved NovoNordisk's(NVO) Wegovy pill. Nicole Petallides has the latest from the health care space ======== Schwab Netwo...
GLP-1 weight-loss pills set to reshape US food demand in 2026
Analysts predict packaged food manufacturers and fast-food eateries may be pushed to alter more of their goods next year when newly licensed appetite-suppressing GLP-1 tablets become accessible in Jan...
Focus: Lilly, Novo lock horns in India's obesity drug race
Global pharma giants Eli Lilly and Novo Nordisk are scrambling to cement their lead in India's booming obesity drug market before cheaper generic versions hit shelves in March next year.
Final Trade: NVO, FCX, BA, CLF
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
Launch of Wegovy pill is core to Novo Nordisk's growth, says Guggenheim's Seamus Fernandez
Guggenheim's Seamus Fernandez joins 'Fast Money' to talk Novo Nordisk getting Wegovy pill approved.
US health agency to expand access to GLP-1 weight-loss drugs
The U.S. Centers for Medicare and Medicaid Services said on Tuesday it will negotiate drug pricing with manufacturers of GLP-1 medications to expand access to the drugs that help with weight loss.
Dr. Ashish Jha talks Novo Nordisk getting approval for Wegovy pill
Dr. Ashish Jha, Brown School of Public Health, joins 'Closing Bell Overtime' to talk Novo Nordisk getting approval fro a Wegovy pill, sending its stock climbing.
Novo Nordisk is still worried about revenue growth next year despite obesity pill: BMO's Seigerman
Evan Seigerman, BMO head of healthcare research, joins 'Power Lunch' to discuss Seigerman's thoughts on Novo Nordisk, its competitor Eli Lilly and much more.
FDA approves Novo Nordisk weight-loss pill. Here's what to know
The U.S. Food and Drug Administration approved Novo Nordisk's weight-loss pill on Monday, giving the Danish drugmaker a leg up in the race to market a potent oral medication for shedding pounds as it ...
Novo Nordisk's Wegovy Pill Shakes Up Rivalry With Eli Lilly, Puts Health Care ETFs In Focus
The approval of Novo Nordisk's (NYSE: NVO)oral Wegovy is bringing new interest to health care and pharmaceutical ETFs that provide access to the growing GLP-1 market without requiring investors to cho...
Novo Nordisk stock: does oral Wegovy approval make it better pick than Eli Lilly?
HSBC's senior research analyst Rajesh Kumar believes Novo Nordisk (NYSE: NVO) “might have an edge” over rival Eli Lilly (NYSE: LLY) heading into 2026. His remarks arrive shortly after the Danish pharm...
Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus
Lexaria Bioscience Corp. (NASDAQ: LEXX) on Tuesday provided an update on its Phase 1b, 12-week chronic study GLP-1-H24-4, recently completed in Australia, focusing on 4 DehydraTECH ( DHT) study arms r...
Novo Nordisk gets US approval for Wegovy obesity pill
Novo Nordisk won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its effort to defend its market share from rival Eli Lilly. President and CEO Mike ...
Could Novo Nordisk's New Weight-Loss Pill Be Just What Its Stock Needs?
Could a new weight-loss pill be just what Novo Nordisk (NVO) needs to revive its stock?
FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk
CNBC's Annika Kim Constantino reports on the FDA's approval of the first GLP-1 pill for obesity from Wegovy maker Novo Nordisk.
Novo Nordisk's Christmas Gift To Shareholders: The Wegovy Pill Has Been Approved
Novo Nordisk A/S secured FDA approval for the oral Wegovy pill, marking a pivotal catalyst for a 2026 turnaround. The Wegovy pill delivers 16.6% weight loss in 64 weeks, outpacing Eli Lilly's Orforgli...
Novo Going 'All-In' With Wegovy Weight Loss Pill
The US will let Novo Nordisk A/S sell it blockbuster weight loss drug Wegovy in a pill form. Millions of people already take the shot.
Novo CEO Says Wegovy Pill Is Safe and Will Be Widely Available
Novo Nordisk President and CEO Mike Doustdar says Christmas has come early with US approval of its Wegovy weight loss pill. He says the company is going "all-in" and they are super excited to be the f...
Eli Lilly Vs. Novo Nordisk: Which Stock Could Lead Pharma's 2026 Comeback
As investors look beyond mega-cap tech for the next leg of growth, pharma is quietly moving back into focus — and no two names capture that shift better than Eli Lilly And Co (NYSE: LLY) and Novo Nord...